OFIXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 23

Orthofix Medical Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$9.59+0.21 (+2.24%)

Close on Oct 19, 2026

Market cap: $392.29M
P/E (TTM): –
Dividend yield: –

Orthofix Medical Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	822	799	747	461	464	407	460	453	434	410	396	402	398	440	436	463	546
Cost of Revenue	256	254	260	124	115	102	101	97	93	88	87	99	107	101	96	97	138
Gross Profit	566	546	486	337	350	305	359	356	341	322	310	303	291	339	339	365	407
Research & Development	66	74	80	49	50	39	35	33	30	29	26	25	27	29	23	28	31
Selling, General & Admin	554	533	530	309	291	272	309	289	270	258	265	246	243	232	250	269	305
Selling & Marketing	–	–	386	229	221	204	224	206	198	181	178	167	175	179	185	196	216
General & Administrative	–	–	145	80	69	68	86	83	72	76	87	79	68	54	65	73	89
Advertising Expenses	–	–	0.50	0.50	0.50	0.90	0.80	0.60	0.70	–	–	–	0.20	0.30	0.50	0.60	0.70
Operating Expenses	–	–	–	–	–	–	378	326	300	301	301	286	302	265	332	299	343
Operating Income	-81	-85	-139	-13	-8.32	-6.27	-19	30	41	21	9.26	17	-11	75	6.61	66	64
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	1.79	1.83	4.16	5.44	11	25
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.33	0.33	0.19
Other Non-Operating Income	8.11	-9.63	-0.94	-3.15	-3.34	8.38	-8.14	-6.38	-4.00	-2.81	-0.26	-2.90	0.59	-5.81	-7.97	-11	-24
Merger & Restructuring Charges	–	9.38	1.18	0.15	0.74	–	–	–	–	2.00	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	12	–	0	–	–	–	–	0.97	19	–	–	–	–
Gain (Loss) on Investments	-0.05	5.12	1.78	0.19	-0.64	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-1.14	-2.03	-2.30	-2.07	–	–	–	–	–	–	3.10	–	–	–	–	8.52	–
Legal Settlements	-34	-16	-14	-0.80	-0.03	–	–	–	–	-14	–	-3.80	-6.70	-1.30	-57	–	–
Pretax Income	-91	-124	-149	-18	-13	-0.37	-27	23	36	19	8.51	12	-11	69	-1.36	55	40
Income Tax Expense	1.38	2.12	2.72	2.04	25	-2.89	1.41	9.07	29	16	11	16	7.60	24	14	-6.03	16
Income from Continuing Operations	–	–	–	–	–	–	-28	14	7.29	3.50	-2.34	-3.74	-18	45	-16	31	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	-4.79	-11	-2.27	-1.89	13	–
Net Income	-92	-126	-151	-20	-38	2.52	-28	14	6.22	3.06	-2.81	-8.54	-29	43	-18	44	–
Net Income to Common	–	–	–	–	–	–	–	–	–	–	-2.81	-8.54	-29	43	-18	44	24
EPS (Basic)(per share)	-2.33	-3.30	-4.12	-0.98	-1.95	0.13	-1.51	0.73	0.34	0.17	-0.15	-0.46	-1.54	2.26	-0.97	2.52	1.43
EPS (Diluted)(per share)	-2.33	-3.30	-4.12	-0.98	-1.95	0.13	-1.51	0.72	0.34	0.17	-0.15	-0.46	-1.54	2.21	-0.97	2.47	1.42
Shares Outstanding (Basic, Weighted)(shares)	40	38	37	20	20	19	19	18	18	18	19	18	19	19	18	18	17
Shares Outstanding (Diluted, Weighted)(shares)	40	38	37	20	20	19	19	19	18	18	19	18	19	19	18	18	17
EBITDA	-4.11	-25	-86	16	21	24	5.92	49	61	42	30	40	12	93	30	88	86
Net Interest Income	-17	-30	-8.63	-1.29	-1.84	-2.48	-0.12	-0.83	-0.42	0.76	-0.49	-1.79	-1.83	–	–	–	–
Provision for Credit Losses	2.26	2.00	0.82	2.10	0.44	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.3%
Operating margin: -4.7%
Net margin: -7.4%
Return on equity, FY2025: -19.3%

Financial strength

Current ratio: 2.84
Debt to equity: 0.52
Debt to assets: 25.4%
Cash to current liabilities: 66.1%

Valuation

P/E ratio: –
Price to sales: 0.47
Price to book: 0.91
Dividend yield: –